Selective ghrelin-receptor (GHS-R1a) agonist
Ipamorelin
Pentapeptide growth-hormone secretagogue with relatively selective GH release and less ACTH/cortisol stimulation than older GHRPs in experimental comparisons.
Primary Mechanism of Action
Clinical / Scientific
Ipamorelin activates the ghrelin GHS-R1a on pituitary and hypothalamic neurons, amplifying GH pulses. It is often combined with GHRH analogues (CJC-1295 no DAC) in research blends because GHRH and ghrelin receptors cooperate on somatotrophs.
Pathway Targets
GHS-R1a (ghrelin receptor)
Scientific explanation
GH-secretagogue agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GHS-R1a (ghrelin receptor)
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GHS-R1a | Agonism | GH pulse amplification | Established mechanism (secretagogue pharmacology) |
Potential Adjunctive Contexts
Mechanistic complementarity with GHRH analogues is the reason “CJC no DAC + ipamorelin” blends exist in research catalogs.
In Plain Language
Ipamorelin mimics ghrelin at the that tells the pituitary to release a pulse of growth hormone.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.